Literature DB >> 32378435

The potential of Slit2 as a therapeutic target for central nervous system disorders.

Prativa Sherchan1, Zachary D Travis2,3, Jiping Tang3, John H Zhang1,4.   

Abstract

Introduction: Slit2 is an extracellular matrix protein that regulates migration of developing axons during central nervous system (CNS) development. Roundabout (Robo) receptors expressed by various cell types in the CNS, mediate intracellular signal transduction pathways for Slit2. Recent studies indicate that Slit2 plays important protective roles in a myriad of processes such as cell migration, immune response, vascular permeability, and angiogenesis in CNS pathologies. Areas covered: This review provides an overview of the diverse functions of Slit2 in CNS disorders and discusses the potential of Slit2 as a therapeutic target. We reviewed preclinical studies reporting the role of Slit2 in various CNS disease models, transgenic animal research, and rodent models that utilized Slit2 as a therapy. Expert opinion: Slit2 exerts a wide array of beneficial effects ranging from anti-migration, blood-brain barrier (BBB) protection, inhibition of peripheral immune cell infiltration, and anti-apoptosis in various disease models. However, a dual role of Slit2 in endothelial permeability has been observed in transgenic animals. Further research on Slit2 will be crucial including key issues such as effects of transgenic overexpression versus exogenous Slit2, function of Slit2 dependent on cellular expression of Robo receptors and the underlying pathology for potential clinical translation.

Entities:  

Keywords:  Anti-migration; Slit2; apoptosis; blood brain barrier; glioma; ischemic stroke; neuroinflammation; roundabout; surgical brain injury; traumatic brain injury

Mesh:

Substances:

Year:  2020        PMID: 32378435      PMCID: PMC7529836          DOI: 10.1080/14728222.2020.1766445

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  96 in total

1.  Over-expression of Slit2 induces vessel formation and changes blood vessel permeability in mouse brain.

Authors:  Hai-xiong Han; Jian-guo Geng
Journal:  Acta Pharmacol Sin       Date:  2011-10-10       Impact factor: 6.150

Review 2.  Slit-Robo signaling.

Authors:  Heike Blockus; Alain Chédotal
Journal:  Development       Date:  2016-09-01       Impact factor: 6.868

3.  Focal adhesion kinase modulates Cdc42 activity downstream of positive and negative axon guidance cues.

Authors:  Jonathan P Myers; Estuardo Robles; Allison Ducharme-Smith; Timothy M Gomez
Journal:  J Cell Sci       Date:  2012-03-05       Impact factor: 5.285

Review 4.  Pericytes and vessel maturation during tumor angiogenesis and metastasis.

Authors:  Ahmad Raza; Michael J Franklin; Arkadiusz Z Dudek
Journal:  Am J Hematol       Date:  2010-08       Impact factor: 10.047

5.  MicroRNA-218 regulates vascular patterning by modulation of Slit-Robo signaling.

Authors:  Eric M Small; Lillian B Sutherland; Kartik N Rajagopalan; Shusheng Wang; Eric N Olson
Journal:  Circ Res       Date:  2010-10-14       Impact factor: 17.367

Review 6.  Slit2-Robo signaling in inflammation and kidney injury.

Authors:  Swasti Chaturvedi; Lisa A Robinson
Journal:  Pediatr Nephrol       Date:  2014-04-29       Impact factor: 3.714

7.  MiR-218 inhibits the tumorgenesis and proliferation of glioma cells by targeting Robo1.

Authors:  Jian-Jun Gu; Guang-Zhong Gao; Shi-Ming Zhang
Journal:  Cancer Biomark       Date:  2016       Impact factor: 4.388

Review 8.  The Role of the Slit/Robo Signaling Pathway.

Authors:  Mingfu Tong; Tie Jun; Yongzhan Nie; Jianyu Hao; Daiming Fan
Journal:  J Cancer       Date:  2019-06-02       Impact factor: 4.207

9.  Abundant expression of guidance and synaptogenic molecules in the injured spinal cord.

Authors:  Anne Jacobi; Anja Schmalz; Florence M Bareyre
Journal:  PLoS One       Date:  2014-02-11       Impact factor: 3.240

10.  Overexpression of Slit2 improves function of the paravascular pathway in the aging mouse brain.

Authors:  Ge Li; Xiaofei He; Hang Li; Yu'e Wu; Yalun Guan; Shuhua Liu; Huanhuan Jia; Yunfeng Li; Lijing Wang; Ren Huang; Zhong Pei; Yue Lan; Yu Zhang
Journal:  Int J Mol Med       Date:  2018-08-02       Impact factor: 4.101

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.